Currently, Recursion Pharmaceuticals Inc [RXRX] is trading at $4.55, up 4.12%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RXRX shares have gain 10.17% over the last week, with a monthly amount drifted -7.52%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Recursion Pharmaceuticals Inc [NASDAQ: RXRX] stock has seen the most recent analyst activity on December 17, 2025, when JP Morgan upgraded its rating to an Overweight but kept the price target unchanged to $11 for it. On May 22, 2023, Morgan Stanley initiated with a Equal-Weight rating and assigned a price target of $8 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $17 on March 16, 2023. KeyBanc Capital Markets initiated its recommendation with an Overweight and recommended $20 as its price target on September 16, 2022. BofA Securities downgraded its rating to Neutral for this stock on April 18, 2022, but kept the price target unchanged to $10. In a note dated March 04, 2022, SVB Leerink downgraded an Mkt Perform rating on this stock but restated the target price of $10.
This stock has fluctuated between a low of $3.79 and a high of $12.36 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Recursion Pharmaceuticals Inc [NASDAQ: RXRX] shares were valued at $4.55 at the most recent close of the market. An investor can expect a potential return of 141.76% based on the average RXRX price forecast.
Analyzing the RXRX fundamentals
Trailing Twelve Months sales for Recursion Pharmaceuticals Inc [NASDAQ:RXRX] were 43.69M which represents -80.16% decline. Gross Profit Margin for this corporation currently stands at -0.04% with Operating Profit Margin at -10.08%, Pretax Profit Margin comes in at -10.07%, and Net Profit Margin reading is -10.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.76 and Total Capital is -0.57. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.38 points at the first support level, and at 4.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.69, and for the 2nd resistance point, it is at 4.83.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Recursion Pharmaceuticals Inc [NASDAQ:RXRX] is 4.60. In addition, the Quick Ratio stands at 4.60 and the Cash Ratio stands at 3.22. Considering the valuation of this stock, the price to sales ratio is 54.20, the price to book ratio is 2.14.
Transactions by insiders
Recent insider trading involved Borgeson Blake, Director, that happened on Jan 06 ’26 when 0.22 million shares were purchased. Director, Gibson Christopher completed a deal on Jan 05 ’26 to buy 40000.0 shares. Meanwhile, Chief Financial Officer Taylor Ben R sold 21383.0 shares on Dec 29 ’25.
